Sponsor
Addpharma Inc.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Addpharma Inc. appears in 21 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
21 shownA Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227BNCT06441630 · lead sponsor · 2024-07-31
RECRUITINGA Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination TherapyNCT07816198 · lead sponsor · 2026-09-30
NOT_YET_RECRUITINGA Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236BNCT07730567 · lead sponsor · 2026-07-29
NOT_YET_RECRUITINGA Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsNCT07717749 · lead sponsor · 2026-07-24
NOT_YET_RECRUITINGA Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231CNCT07590167 · lead sponsor · 2026-06-01
NOT_YET_RECRUITINGA Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult SubjectsNCT07476157 · lead sponsor · 2026-04-01
NOT_YET_RECRUITINGA Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232NCT07538466 · lead sponsor · 2026-04-01
NOT_YET_RECRUITINGEvaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322NCT07312799 · lead sponsor · 2026-01-27
NOT_YET_RECRUITINGA Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231CNCT07312773 · lead sponsor · 2026-01-23
NOT_YET_RECRUITINGA Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227BNCT06884085 · lead sponsor · 2025-07-12
COMPLETEDPhase III Study to Evaluate the Efficacy and Safety of AD-209NCT06348576 · lead sponsor · 2024-05-20
UNKNOWNA Study to Evaluate the Efficacy and Safety of AD-224NCT06291207 · lead sponsor · 2024-04-15
COMPLETEDA Study to Evaluate the Efficacy and Safety of AD-223NCT06052748 · lead sponsor · 2024-02-15
COMPLETEDA Study to Evaluate the Efficacy and Safety of AD-209NCT05631990 · lead sponsor · 2023-04-05
COMPLETEDEvaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102NCT04600284 · lead sponsor · 2020-11-16
COMPLETEDPhase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022NCT06448962 · lead sponsor · 2020-10-22
COMPLETEDDetermining the Optimal Dose of AD-209 in Patients With Essential HypertensionNCT04218552 · lead sponsor · 2020-02-25
COMPLETEDEvaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/AmlodipineNCT04158076 · lead sponsor · 2020-01-23
COMPLETEDEvaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and TelmisartanNCT03872232 · lead sponsor · 2019-02-26
COMPLETEDEvaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072NCT03632668 · lead sponsor · 2018-09-28
COMPLETEDEvaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012NCT03586037 · lead sponsor · 2018-06-12
COMPLETEDSponsor roles
lead sponsor21
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.